Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC)
Mutations in the tyrosine kinase (TKD) domain of the epidermal growth factor receptor (EGFR) are involved in the unfavorable therapeutic response through resistance to targeted molecular therapy. Data from the clinical experience of non-small cell lung carcinoma (NSCLC) treatment demonstrate the ben...
Main Authors: | Camil Ciprian MIRESTEAN, Roxana Irina IANCU, Dragos Teodor IANCU |
---|---|
Format: | Article |
Language: | English |
Published: |
Media Med Publicis
2022-09-01
|
Series: | Modern Medicine |
Subjects: | |
Online Access: | https://medicinamoderna.ro/wp-content/uploads/2022/09/Targeting-EGFR-Exon-20-Insertion-mutated-Cancers-%E2%80%93-New-Perspectives-in-Head-and-Neck-Cancers.pdf |
Similar Items
-
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
by: Zhang SS, et al.
Published: (2021-07-01) -
Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
by: Vishal Shah, et al.
Published: (2023-03-01) -
Uncommon and Rare <i>EGFR</i> Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art
by: Federico Pio Fabrizio, et al.
Published: (2024-03-01) -
Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
by: Petrini I, et al.
Published: (2022-10-01) -
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
by: Samy Chelabi, et al.
Published: (2021-10-01)